Limouris GS - Search Results

1

Palliative therapy using rhenium-186-HEDP in painful breast osseous metastases.

Limouris GS, Shukla SK, Condi-Paphiti A, Gennatas C, Kouvaris I, Vitoratos N, Manetou A, Dardoufas C, Rigas V, Vlahos L. Limouris GS, et al. Anticancer Res. 1997 May-Jun;17(3B):1767-72. Anticancer Res. 1997. PMID: 9179232 Clinical Trial.

2

Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer.

Limouris G, Shukla SK, Manetou A, Kouvaris I, Plataniotis G, Triantafyllou N, Rigas AV, Vlahos L. Limouris G, et al. Anticancer Res. 1997 May-Jun;17(3B):1699-704. Anticancer Res. 1997. PMID: 9179222 Clinical Trial.

3

Effects in the testes after SPECT myocardial perfusion with Tl-201 or Tc-99m hexaMIBI.

Manetou A, Limouris GS. Manetou A, et al. Among authors: limouris gs. Anticancer Res. 1997 May-Jun;17(3B):1841-4. Anticancer Res. 1997. PMID: 9179242

4

Somatostatin receptor scintigraphy of non-neuroendocrine malignancies with 111In-pentetreotide.

Limouris GS, Rassidakis A, Kondi-Paphiti A, Triantafyllou N, Manetou A, Giannakopoulos V, Toubanakis N, Psyhojios I, Stavraka A, Vlahos L. Limouris GS, et al. Anticancer Res. 1997 May-Jun;17(3B):1593-7. Anticancer Res. 1997. PMID: 9179200

5

99mTc-antigranulocyte bone marrow scintigraphy of breast and prostate skeletal metastases.

Limouris GS, Voliotopoulos V, Stavraka A, Vlahos L. Limouris GS, et al. Anticancer Res. 1997 May-Jun;17(3B):1615-8. Anticancer Res. 1997. PMID: 9179204

6

Predictive implications of bone turnover markers after palliative treatment with (186)Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases.

Zafeirakis A, Papatheodorou G, Arhontakis A, Gouliamos A, Vlahos L, Limouris GS. Zafeirakis A, et al. Among authors: limouris gs. Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):103-13. doi: 10.1007/s00259-009-1243-5. Eur J Nucl Med Mol Imaging. 2010. PMID: 19662405 Clinical Trial.

7

Gastric uptake during Re-186 HEDP bone scintigraphy.

Limouris GS, Skukla SK. Limouris GS, et al. Anticancer Res. 1997 May-Jun;17(3B):1779-81. Anticancer Res. 1997. PMID: 9179234

8

Receptor scintigraphy of non-neuroendocrine cancers with In-111 pentetreotide.

Limouris GS, Rassidakis A, Kondi-Paphiti A, Triantafyllou N, Manetou A, Gennatas K, Vitoratos N, Gregoriou O, Stavraka A, Vlahos L. Limouris GS, et al. Hybridoma. 1997 Feb;16(1):133-7. doi: 10.1089/hyb.1997.16.133. Hybridoma. 1997. PMID: 9085140

9

Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors.

Limouris GS, Giannakopoulos V, Stavraka A, Toubanakis N, Vlahos L. Limouris GS, et al. Anticancer Res. 1997 May-Jun;17(3B):1589-92. Anticancer Res. 1997. PMID: 9179199

10

Two phase scintigraphic mapping of lymphatic drainage in cutaneous melanoma using 99mTc-sulfur microcolloid/99mTc antimelanoma antibody.

Limouris GS, Voliotopoulos V, Kondi-Paphiti A, Stavraka A, Vlahos L. Limouris GS, et al. Anticancer Res. 1997 May-Jun;17(3B):1667-9. Anticancer Res. 1997. PMID: 9179215

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters